JOP20220154A1 - مشتقات سبيرو بسلسلة مستقيمة بها استبدال - Google Patents

مشتقات سبيرو بسلسلة مستقيمة بها استبدال

Info

Publication number
JOP20220154A1
JOP20220154A1 JOP/2022/0154A JOP20220154A JOP20220154A1 JO P20220154 A1 JOP20220154 A1 JO P20220154A1 JO P20220154 A JOP20220154 A JO P20220154A JO P20220154 A1 JOP20220154 A1 JO P20220154A1
Authority
JO
Jordan
Prior art keywords
straight chain
substituted straight
spiro derivatives
useful
spiro
Prior art date
Application number
JOP/2022/0154A
Other languages
English (en)
Inventor
Gregor Thomas Urbanietz
Alicia Tee Fuay Ng
Vineet Pande
Johannes Wilhelmus John F Thuring
Nicolas Freddy J Darville
Xuedong Dai
Xiangjun Deng
Qiwu Zhao
Yanping Xu
Wei Cai
Lichao Fang
Liqiang Fu
Edward Cleator
Olivier Alexis Georges Querolle
Kangying Li
Ming Li
Lianzhu Liu
Yingtao Liu
William Marc Maton
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76476870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20220154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20220154A1 publication Critical patent/JOP20220154A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بعوامل صيدلانية مفيدة للعلاج و/ أو الوقاية في كائن ثديي، وتركيبة صيدلانية تشتمل على هذه المركبات، واستخدامها كمثبطات تداخل بروتين/ بروتين مينين/ MLL، مفيدة لعلاج الأمراض مثل سرطان، بما في ذلك بدون حصر سرطان الدم، متلازمة خلل التنسج النقوي (MDS)، والأورام النخاعية التكاثرية (MPN)؛ والسكري.
JOP/2022/0154A 2019-12-19 2022-06-16 مشتقات سبيرو بسلسلة مستقيمة بها استبدال JOP20220154A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019126760 2019-12-19
US202062961775P 2020-01-16 2020-01-16
CN2020126595 2020-11-04
PCT/CN2020/137266 WO2021121327A1 (en) 2019-12-19 2020-12-17 Substituted straight chain spiro derivatives

Publications (1)

Publication Number Publication Date
JOP20220154A1 true JOP20220154A1 (ar) 2022-06-16

Family

ID=76476870

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0154A JOP20220154A1 (ar) 2019-12-19 2022-06-16 مشتقات سبيرو بسلسلة مستقيمة بها استبدال

Country Status (21)

Country Link
US (1) US12473295B2 (ar)
EP (1) EP4077312A4 (ar)
JP (3) JP7554829B2 (ar)
KR (1) KR20220118500A (ar)
CN (4) CN114867721A (ar)
AU (1) AU2020404305B2 (ar)
CA (1) CA3161045A1 (ar)
CL (3) CL2022001583A1 (ar)
CO (1) CO2022009085A2 (ar)
CR (1) CR20220346A (ar)
DO (1) DOP2022000125A (ar)
EC (1) ECSP22054700A (ar)
IL (1) IL293965B1 (ar)
JO (1) JOP20220154A1 (ar)
MX (1) MX2022007652A (ar)
PE (1) PE20230162A1 (ar)
PH (1) PH12022551502A1 (ar)
TW (2) TW202525813A (ar)
UA (1) UA129208C2 (ar)
UY (1) UY38988A (ar)
WO (1) WO2021121327A1 (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
BR112023021040A2 (pt) * 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
AU2022274071A1 (en) 2021-05-11 2024-01-04 Janssen Pharmaceutica Nv Combination therapies
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253289A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) * 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
EP4271676B1 (en) * 2021-12-03 2026-07-01 Les Laboratoires Servier DIAZASPIRO CARBONYL SUBSTITUTE COMPOUNDS AND THEIR USE
WO2024046457A1 (en) * 2022-09-02 2024-03-07 Hutchmed Limited Triazine compounds and uses thereof
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
KR20250170131A (ko) 2023-04-17 2025-12-04 얀센 파마슈티카 엔브이 조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물
KR20260099138A (ko) 2023-10-20 2026-06-26 얀센 파마슈티카 엔브이 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법
KR20260115654A (ko) 2023-12-04 2026-07-24 쇼우야오 홀딩스 (베이징) 코., 엘티디. 치환된 다환 화합물
CN120365200B (zh) * 2025-04-18 2025-11-11 北京蓝博特科技有限公司 一种(s)-2-(3,5-二甲基苯基)吡咯烷盐酸盐的制备方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2791732B2 (ja) 1992-04-02 1998-08-27 小野薬品工業株式会社 ３′−アミノ−２′−ヒドロキシアセトフェノンの製造方法
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
WO2003070739A1 (en) 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
CA2509406C (en) 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
JP4545196B2 (ja) 2005-01-19 2010-09-15 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
WO2010041366A1 (ja) 2008-10-06 2010-04-15 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及び記録媒体
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
CN102471291B (zh) 2009-08-20 2015-04-22 拜尔农作物科学股份公司 用作杀螨剂和杀昆虫剂的3-三唑基苯基取代的硫化物衍生物
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9586961B2 (en) 2010-07-09 2017-03-07 Leo Pharma A/S Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
GB201021623D0 (en) 2010-12-21 2011-02-02 Isis Innovation Detection of acute myeloid leukaemia
WO2013014162A1 (en) 2011-07-28 2013-01-31 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
WO2013018404A1 (ja) 2011-08-01 2013-02-07 オリンパスメディカルシステムズ株式会社 挿入部形状表示装置
CN103889983B (zh) 2011-09-14 2015-12-09 普罗克西梅根有限公司 酶抑制剂化合物
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
MX2015006191A (es) 2012-11-16 2015-08-10 Merck Sharp & Dohme Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
US9708568B2 (en) 2014-05-06 2017-07-18 The Procter & Gamble Company Fragrance compositions
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN105330698B (zh) 2014-07-04 2019-05-28 齐鲁制药有限公司 螺环芳基磷氧化物和硫化物
JP6487527B2 (ja) * 2014-07-04 2019-03-20 チル ファーマシューティカル カンパニー リミテッド スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
EP3207030A4 (en) 2014-10-14 2018-06-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10526341B2 (en) 2014-11-19 2020-01-07 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
PL3233857T3 (pl) 2014-12-18 2020-07-27 Takeda Pharmaceutical Company Limited Stałe postacie skondensowanych heteroaromatycznych pirolidynonów
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
BR112018012707A2 (pt) 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
AU2017212572A1 (en) 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
JP7071644B2 (ja) 2016-09-06 2022-05-19 株式会社スリーボンド 熱硬化型導電性接着剤
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
SG11201911859QA (en) 2017-06-16 2020-01-30 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
IL271946B (en) 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
GB201720077D0 (en) 2017-12-01 2018-01-17 Univ Oxford Innovation Ltd Leukaemic stem cell
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
TWI815954B (zh) 2018-08-27 2023-09-21 日商住友製藥股份有限公司 光學活性氮雜雙環衍生物
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
JP7594787B2 (ja) 2018-12-07 2024-12-05 ユニバーシティ オブ メリーランド、ボルチモア 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
JP7319395B2 (ja) 2019-06-14 2023-08-01 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
KR102924600B1 (ko) 2019-12-18 2026-02-09 솔루스첨단소재 주식회사 유기 화합물 및 이를 이용한 유기 전계 발광 소자
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
CN111297863B (zh) 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
WO2022114164A1 (ja) 2020-11-30 2022-06-02 アステラス製薬株式会社 ヘテロアリールカルボキシアミド化合物
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
BR112023021040A2 (pt) 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
AU2022274071A1 (en) 2021-05-11 2024-01-04 Janssen Pharmaceutica Nv Combination therapies
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
JP2024520900A (ja) 2021-05-12 2024-05-27 シンダックス ファーマシューティカルズ， インコーポレイテッド 癌の治療のための組合せ
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253289A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
EP4271676B1 (en) * 2021-12-03 2026-07-01 Les Laboratoires Servier DIAZASPIRO CARBONYL SUBSTITUTE COMPOUNDS AND THEIR USE
MX2024007201A (es) 2021-12-15 2024-08-06 Dana Farber Cancer Inst Inc Direccionamiento terapeutico del tumor del estroma gastrointestinal (gist) mediante la alteracion del complejo epigenetico de menina-mll.
WO2023150635A1 (en) * 2022-02-04 2023-08-10 Kura Oncology, Inc. Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors
CN120514709A (zh) 2022-05-09 2025-08-22 赛达克斯制药股份有限公司 用于治疗癌症的menin-mll抑制剂
EP4626885A1 (en) 2022-11-30 2025-10-08 Janssen Pharmaceutica NV Cyclobutyl substituted bicyclic compounds
WO2024114658A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives
JP2025540762A (ja) 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ阻害剤及びｂｃｌ－２阻害剤を含む組み合わせ
JP2025540759A (ja) 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ阻害剤及び少なくとも１つの他の治療剤を含む組み合わせ
KR20250170131A (ko) 2023-04-17 2025-12-04 얀센 파마슈티카 엔브이 조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물

Also Published As

Publication number Publication date
WO2021121327A1 (en) 2021-06-24
US12473295B2 (en) 2025-11-18
IL293965A (en) 2022-08-01
CN118255774A (zh) 2024-06-28
DOP2022000125A (es) 2022-08-31
AU2020404305A1 (en) 2022-08-04
CN114867721A (zh) 2022-08-05
IL293965B1 (en) 2026-05-01
CL2023001531A1 (es) 2023-11-03
JP2023506530A (ja) 2023-02-16
CN118344372A (zh) 2024-07-16
TW202138367A (zh) 2021-10-16
CR20220346A (es) 2022-10-26
KR20220118500A (ko) 2022-08-25
UA129208C2 (uk) 2025-02-05
ECSP22054700A (es) 2022-11-30
JP2024138279A (ja) 2024-10-08
PE20230162A1 (es) 2023-02-01
CL2023001530A1 (es) 2023-11-03
CN118255773A (zh) 2024-06-28
CL2022001583A1 (es) 2023-02-03
MX2022007652A (es) 2022-09-23
EP4077312A1 (en) 2022-10-26
AU2020404305B2 (en) 2026-04-23
JP7781961B2 (ja) 2025-12-08
UY38988A (es) 2021-06-30
US20230142285A1 (en) 2023-05-11
TW202525813A (zh) 2025-07-01
JP7554829B2 (ja) 2024-09-20
TWI878414B (zh) 2025-04-01
PH12022551502A1 (en) 2023-04-24
CO2022009085A2 (es) 2022-07-08
EP4077312A4 (en) 2024-01-17
CA3161045A1 (en) 2021-06-24
JP2026035699A (ja) 2026-03-04

Similar Documents

Publication Publication Date Title
PH12022551502A1 (en) Substituted straight chain spiro derivatives
MX2023014347A (es) Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos.
MX2023013174A (es) Derivados espiro sustituidos.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
MX389598B (es) Inhibidores bicíclicos condensados de la interacción de menina-mll.
MX392051B (es) Inhibidores espirobiciclicos de la interaccion de menina-mll
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ZA202408030B (en) Tricyclic heterocyclic derivatives, compositions and uses thereof
BR112023021040A2 (pt) Derivados espiro substituídos
AR062391A1 (es) Uso de compuestos y derivados de 2,5 dihidroxibenceno para el tratamiento de dicracias hematologicas y cancer de un organo
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
PH12023553300A1 (en) (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
MX2025012818A (es) Derivados de heterociclicos triciclicos, composiciones y usos de estos
MX391405B (es) Inhibidores de azepano de la interacción menina-mll.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
BR112023025436A2 (pt) Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
PL442547A1 (pl) Pochodne 4-arylotiosemikarbazydu do zastosowania w leczeniu toksoplazmozy
EA201990700A1 (ru) Конденсированные бициклические ингибиторы взаимодействия менин–mll
TNSN06305A1 (en) Treatment regimen for camptothecin derivatives